Protein-protein interactions in neurodegenerative disorders
AssigneeMyriad Genetics, Inc.
InventorsJean-Marc Roch, Paul L. Bartel
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.
Claims42
A method for modulating, in a cell, a protein complex having a first protein which is acetylcholine esterase interacting with a second protein which is KIAA0436, said method comprising:
- administering to said cell a compound capable of modulating said protein complex.
A method for modulating, in a cell, a protein complex having a first protein which is acetylcholine esterase interacting with a second protein which is KIAA0436, said method comprising:
- administering to said cell a peptide capable of interfering with the interaction between said first protein and said second protein, wherein said peptide is associated with a transporter capable of increasing cellular uptake of said peptide.
A method for modulating, in a cell, the interaction of KIAA0436 with a ligand, said method comprising:
- administering to said cell a compound capable of modulating said interaction.
A method for modulating a proteolyic event in the brain of a patient having a neurodegenerative disorder comprising:
- modulating a protein complex having a first protein which is acetylcholine esterase interacting with a second protein which is KIAA0436.
A method for modulating a proteolyic event in the brain of a patient having neurodegenerative disorder comprising:
- administering to the patient a compound capable of modulating a protein complex having a first protein which is acetylcholine esterase interacting with a second protein which is KIAA0436.
A method for treating a neurodegenerative disorder comprising:
- administering to a patient in need of treatment a compound capable of modulating a protein complex having a first protein which is acetylcholine esterase interacting with a second protein which is KIAA0436.
A method for treating a neurodegenerative disorder comprising:
- administering to a patient in need of treatment a compound capable of modulating the activity of KIAA0436.
Dependencies are inferred from the claim text.